TICKERNERD
Menu
BCPCBCPCBasic Materials · Specialty Chemicals

BCPC Stock Forecast: Balchem Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$179
+0.77% on the day

The 3 Wall Street analysts covering Balchem Corp. hold a median 12-month price target of $215 — +20.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$5.7B
Ticker Nerd rank
93 / 100
Median analyst target
$215
Analysts covering
3
Total return, dividends reinvested
1W
−0.5%
1M
+11.0%
YTD
+16.4%
1Y
+11.6%
From 52W high
−2.6%
From 52W low
+28.0%
$139
$183
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BCPC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Balchem Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Revisions
96
Quality
94
Issuance
93
Growth
62
Momentum
60
Accruals
55
Value
49
Size
22

Volatility (97): The share price has been relatively steady.

Value (49): The shares cost a lot relative to the profits and assets behind them.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BCPC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCPC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$140$160$180$200$220$240Oct 25Jan 26Apr 26Jul 26BCPCHigh $242Median $215Low $165

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $165Median $215High $242

The green dot is the last close — the median target sits +20.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026HC Wainwright & Co.MaintainsBuy$190 → $215
4 May 2026HC Wainwright & Co.MaintainsBuy—
4 May 2026HC Wainwright & Co.MaintainsBuy$5.10 → $5.16
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
5 Dec 2025Rothschild & CoInitiatesNeutral—
22 Oct 2025HC Wainwright & Co.MaintainsBuy—
4 Aug 2025HC Wainwright & Co.MaintainsBuy—
28 Apr 2025HC Wainwright & Co.MaintainsBuy—
24 Feb 2025HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024HC Wainwright & Co.MaintainsBuy—
31 July 2024HC Wainwright & Co.MaintainsBuy—
6 May 2024HC Wainwright & Co.MaintainsBuy—
20 Feb 2024HC Wainwright & Co.MaintainsBuy—
30 Oct 2023HC Wainwright & Co.MaintainsBuy—
31 July 2023HC Wainwright & Co.MaintainsBuy—
5 June 2023HC Wainwright & Co.MaintainsBuy—
27 Feb 2023HC Wainwright & Co.MaintainsBuy—
7 Nov 2022HC Wainwright & Co.MaintainsBuy—
22 Aug 2022HC Wainwright & Co.MaintainsBuy—
2 May 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BCPC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BCPC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.7%
Analysts raising
1
Analysts cutting
1
Fundamentals

Balchem Corp. (BCPC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
34.9×

Cheaper than 24% of US stocks

Price / sales
5.2×

Cheaper than 24% of US stocks

Price / book
4.4×

Cheaper than 25% of US stocks

EV / EBITDA
21.3×

Cheaper than 15% of US stocks

Growth & margins
Revenue growth (YoY)
11.2%

Higher than 56% of US stocks

Earnings growth (YoY)
16.6%

Higher than 55% of US stocks

Gross margin
37.3%

Higher than 47% of US stocks

Operating margin
20.9%

Higher than 80% of US stocks

Net margin
15.1%

Higher than 78% of US stocks

Returns & dividend
Return on equity
12.8%

Higher than 70% of US stocks

Return on assets
8.2%

Higher than 88% of US stocks

Dividend yield
2.2%

Higher than 48% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BCPC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSpecialty Chemicals
CompanyMarket capTKN rank
BCPCBalchem Corp.$5.7B
93
SXTSensient Technologies Corp.$5.7B
65
PRMPerimeter Solutions, Inc.$5.5B
21
CBTCabot Corp.$4.6B
87
AVNTAvient Corp.$4.2B
94
AXTAAxalta Coating Systems Ltd.$8.0B
86
CLMTCalumet, Inc.$4.2B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Balchem Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCPC news & analysis

Balchem: It's A Buy From Me After Posting Strong Q2 Results

Seeking Alpha · 2 Aug 2026positive

Balchem Corporation reported Q2 results with EPS of $1.49, beating estimates by $0.07, and revenue that surpassed consensus by $15 million while rising 11% year over year. All business segments posted growth, ranging from a minimum of 8.9% to a peak of 15% in Animal Nutrition & Health.

Why it matters — A BCPC watcher would care because double-digit revenue growth and beats across every segment indicate broad-based, company-wide momentum in the latest quarter.

Balchem Corporation (BCPC) Q2 2026 Earnings Call Transcript

Seeking Alpha · 31 July 2026neutral

Seeking Alpha published the transcript of Balchem Corporation's Q2 2026 earnings call.

Why it matters — Earnings call transcripts provide direct insight into management's commentary on quarterly results and the company's outlook.

Conestoga SMid Cap Composite Q2 2026 Portfolio Review

Seeking Alpha · 31 July 2026neutral

The Conestoga SMid Cap Composite Q2 2026 Portfolio Review noted that West Pharmaceuticals stock rose on broad-based growth in biologics packaging, Tyler Technologies underperformed despite solid results, and Knowles was highlighted for its accelerating organic growth and expanding margins.

Why it matters — While the review does not directly mention Balchem, its commentary on trends in specialty packaging, biologics, and mid-cap growth companies may provide relevant context for Balchem's competitive landscape.

Balchem Corporation Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 31 July 2026neutral

Balchem Corporation announced its financial results for the second quarter of fiscal 2026, which ended June 30, 2026.

Why it matters — BCPC watchers would care because the quarterly financial results provide a key update on the company's recent performance and financial health.

FAQ

Frequently asked questions about BCPC stock

What is the BCPC stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Balchem Corp. have a median 12-month price target of $215, with estimates ranging from $165 to $242. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BCPC stock a buy right now?

Of the 3 analysts covering Balchem Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Balchem Corp. 93 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCPC?

As at 15 Aug 2026, Balchem Corp. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will BCPC stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +20.4% from the last close, and Ticker Nerd's factor model ranks Balchem Corp. 93 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BCPC stock forecast for 2030?

No analyst covering Balchem Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCPC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $242 over the next 12 months.

How has BCPC stock performed over the past year?

Balchem Corp. returned +11.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Balchem Corp. do?

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for diverse industries worldwide. Operating through three key segments, it leads in Human Nutrition and Health, providing human-grade choline nutrients, mineral amino acid chelated products, and ingredients for food, beverage, pharmaceutical, and health applications.

What is the latest news on BCPC?

The most recent item we track (Seeking Alpha, 2 Aug 2026): "Balchem: It's A Buy From Me After Posting Strong Q2 Results". Balchem Corporation reported Q2 results with EPS of $1.49, beating estimates by $0.07, and revenue that surpassed consensus by $15 million while rising 11% year over year. All business segments posted growth, ranging from a minimum of 8.9% to a peak of 15% in Animal Nutrition & Health.

Company

About Balchem Corp.

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for diverse industries worldwide. Operating through three key segments, it leads in Human Nutrition and Health, providing human-grade choline nutrients, mineral amino acid chelated products, and ingredients for food, beverage, pharmaceutical, and health applications. The Animal Nutrition and Health segment delivers nutritional solutions derived from microencapsulation and chelation technologies, including essential nutrient choline chloride for animal feed. The Specialty Products segment focuses on repackaging and distributing performance gases and chemicals for medical device sterilization, plant nutrition, and industrial uses. Balchem Corporation serves nutritional, food, pharmaceutical, animal health, and industrial markets, emphasizing innovative solutions that enhance health and performance. Founded in 1967 and headquartered in New Jersey, it plays a vital role in the specialty chemicals sector by supplying high-quality, technology-driven ingredients to support global health, nutrition, and industrial needs.

CEO Mr. Theodore Lee Harris · 1,379 employees · United States · https://www.balchem.com